Researchers said a new kind of cholesterol-modifying drug from Merck demonstrated remarkably strong LDL-lowering and HDL-raising effects, and appeared safe from a cardiovascular standpoint, stoking doctors' optimism that it could reach market.
Phase III data reported yesterday at the AHA Meeting in Chicago showed that new blood thinner Xarelto (rivaroxaban) stacks up well against warfarin in preventing strokes in patients with atrial fibrillation.
A love-hate relationship for Coumadin (warfarin) is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.
Generics and specialty pharma Watson acquired a progesterone gel, marketed as Crinone and Prochieve, and added roughly 19 reps to its women's health sales force. Watson now employs close to 400 reps, according to Charlie Mayr, a company spokesperson.
To those who believe we have everything we need in the lipid-lowering world, Ben Stakely, Kowa Pharmaceuticals America (KPA) CEO and president, has one thing to say: "I would argue with you."
A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.
Sanofi-Aventis partnered with Cegedim Dendrite to launch a CRM mobile platform for its managed market managers. The three-year agreement spans 28 countries, including the US, France and Japan.
If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.
AstraZeneca will help Abbott reach more physicians with its Trilipix (fenofibric acid) drug, a cholesterol product approved by FDA last December. The companies also filed an NDA for Certriad, a Trilipix/Crestor combination drug.
GlaxoSmithKline will partner with Shire to co-promote Vyvanse, Shire's Adderall follow-on ADHD drug. The three-year deal will double the brand's sales force, with 600 GSK reps targeting primary care physicians and specialists, the companies announced today.
Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.
Allergan is gearing up for the launch of Latisse, the first FDA-approved cosmetic eyelash enhancer, with a website and consumer ads in development.
Results from a large national study may have put the nail in the coffin of hormone replacement therapy (HRT) treatments, the Associated Press reported Saturday.
J&J flaunted the benefits of its diversified and globalized business portfolio today, reporting respectable third-quarter results despite static worldwide pharmaceutical sales of $6.1 billion.
Amgen announced plans to restructure its sales practices for Aranesp, a anemia drug used primarily for chemotherapy patients
Teva is buying Montvale, NJ-based Barr Pharmaceuticals for $7.4 billion and will take on debt of $1.5 billion.
Bayer HealthCare Pharmaceuticals announced that a reformulation of the liquid Leukine (sargramostim) has been approved by FDA and is now available for patients and physicians in the US.
Canadian regulators have approved Novartis' Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE) inhibitors, a common type of heart failure therapy.
Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.
Cephalon announced that the FDA has approved Treanda (bendamustine hydrochloride) for injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease.
Hawthorn Pharmaceuticals announced the FDA approval of the company's Granisol (granisetron HCl) oral solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy.
Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.
The FDA approved Wyeth's Pristiq (desvenlafaxine) to treat adult patients with major depressive disorder. Wyeth expects to begin shipping Pristiq to wholesalers beginning in the second quarter of 2008.
The FDA approved AstraZeneca's Nexium (esomeprazole magnesium) for short-term use in children ages one -11 years for the treatment of gastroesophageal reflux disease (GERD).
Sciele Pharma expaned its alliance with Sanofi-Aventis with a new exclusive, three-year agreement to market Allegra orally disintegrating tablets (ODT) and Allegra oral suspension in the pediatric market in the US.
Eli Lilly announced the launch of KwikPen, a new insulin pen prefilled with Humalog (insulin lispro injection).
The FDA has approved UCB and Sanofi-Aventis' NDA for Xyzal (levocetirizine dihydrochloride) 0.5 mg/ml oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
Bentley Pharmaceuticals announced its European subsidiaries have received approvals to market their omeprazole capsule products, through their licensees, in various territories in Europe.
AstraZeneca submitted applications in the European Union for once-daily Seroquel XR (quetiapine fumarate), seeking approval for the treatment of manic episodes associated with bipolar disorder and the treatment of depressive episodes associated with bipolar disorder.
Schering-Plough posted a fourth quarter loss on charges related to its acquisition of Organon and said it was ready to take action if sales of Vytorin and Zetia decline significantly.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.